Medical Oncology

Thyroid Cancer

Questions discussed in this category

How do you approach a young patient with metastatic poorly differentiated thyroid cancer with rhabdoid/non-anaplastic features?

4 Answers available

What factors aside from progression do you consider most important in determining whether a patient with metastatic papillary thyroid carcinoma is radioactive iodine refractory?

What is your evaluation approach for RAI response? What cumulative dose do you use in practice for deciding a patient is RAI refractory?

1 Answer available

When would you offer post-operative concurrent chemoradiation in anaplastic thyroid cancer?

Would you consider it for a patient with good PS but with limited metastatic disease? What dose fractionation would you prefer?

1 Answer available

How do you approach patients with recurrent papillary thyroid cancer following thyroidectomy who now has palpable cervical nodes and underwent neck dissection and RAI?

1 Answer available

Would you offer a RET inhibitor for a RET-mutated medullary thyroid carcinoma after R1 resection in a patient with elevated calcitonin?

What factors may favor RET inhibition versus observation?

1 Answer available

What is your preferred approach to adjuvant therapy for a Masaoka Stage III thymic carcinoma after R1 resection?

Would you elect for concurrent chemoRT or RT alone?

1 Answer available

How would you approach patient with metastatic anaplastic thyroid cancer with NGS revealing only ARID1A mutation?

1 Answer available

Would you offer, and what data would support, the use of an FGFR inhibitor in FGFR3 mutated anaplastic thyroid cancer?

1 Answer available

What treatment would you initiate post-operatively for patients with de novo metastatic follicular thyroid CA requiring laminectomy for cord compression?

In addition to TSH suppression, would you opt for RAI, targeted treatment based off NGS, or lenvatinib?

1 Answer available

Is there any contraindication to concurrent administration of radioactive iodine in a patient on immunotherapy?

A patient with stage 3 melanoma on adjuvant nivolumab needs radioactive iodine for papillary thyroid cancer.

1 Answer available

Would you consider low dose lenvatinib or dabrafenib/trametinib for rapidly progressive RAI refractory thyroid cancer with BRAF V600E mutation in a patient in whom you are concerned about tolerance of full dose lenvatinib?

Such as in patients who are elderly or have borderline performance status

1 Answer available

For patients with metastatic radioctive iodine refractory papillary thyroid carcinoma that is BRAF V600E mutant and rapidly progressive, would you consider dabrafenib/trametinib combo instead of lenvantinib or sorafenib first line?

Aggressive histology with tall cell variant papillary thyroid carcinoma that's progressed 2 months after RAI and while on TSH suppression, without tra...

1 Answer available

Do you prefer rhTSH for TSH stimulation instead of thyroid hormone withdrawal when treating patients with radioactive iodine for papillary thyroid carcinoma?

If not, what is your thyroid hormone withdrawal protocol? If so, would you still treat a patient with possibly metastatic disease?

1 Answer available

Papers discussed in this category

N. Engl. J. Med., 2012-05-03

Strategies of radioiodine ablation in patients with low-risk thyroid cancer.

N. Engl. J. Med., 2012-05-03

Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer.

The New England journal of medicine, 2015-02-12

Lenvatinib versus placebo in radioiodine-refractory thyroid cancer.

Cancer discovery, 2015-07

ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP Inhibitors.

J Immunother Cancer,

alterations function as a biomarker for longer progression-free survival after anti-PD-1/PD-L1 immunotherapy.

Related Topics in Medical Oncology